Cyclacel Pharmaceuticals Inc.
418 articles about Cyclacel Pharmaceuticals Inc.
-
Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -
8/12/2020
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel's novel CDK2/9 inhibitor. The Company's net loss applicable to common shareholders for the three months
-
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results
8/5/2020
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on Wednesday, August 12, 2020.
-
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
7/13/2020
Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC
-
Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results
5/12/2020
Cyclacel Pharmaceuticals, Inc. reported its financial results for the first quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel's novel CDK inhibitor.
-
Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results
5/5/2020
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2020 financial results on Tuesday, May 12, 2020.
-
Cyclacel Announces Closing of $20 Million Public Offering
4/24/2020
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced public offering of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) common warrants to purchase up to 4,000,000 shares of common stock.
-
CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
4/21/2020
Cyclacel Pharmaceuticals, Inc. announced the pricing of a public offering with expected total gross proceeds of approximately $20 million, before deducting placement agent fees and other offering expenses payable by the Company.
-
Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
4/20/2020
Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
-
Cyclacel Announces Reverse Stock Split - April 14, 2020
4/14/2020
Cyclacel Pharmaceuticals, Inc. announced that effective at 5:00 p.m., Eastern Time, on April 14, 2020, the Company will effect a one-for-twenty reverse stock split of its outstanding common stock.
-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2/26/2020
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2019.
-
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
2/19/2020
BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call:
-
Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference
2/3/2020
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO & Investor Conference at 11:15 a.m. EST on Monday, February 10, in the Wilder Room at the New York Marriott Marquis
-
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
1/13/2020
Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors andCYC065-venetoclax combination in AML/MDS and CLL dose escalation studies
-
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
1/6/2020
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™ 2020, at 9:30 a.m. PT on January 13,
-
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
12/9/2019
CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies
-
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
11/13/2019
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlights for the third quarter 2019.
-
Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results
11/7/2019
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Wednesday, November 13, 2019.
-
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
11/6/2019
Cyclacel Pharmaceuticals, Inc. announced that data from Cyclacel’s CYC065 and sapacitabine ongoing clinical studies have been selected for presentation at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.
-
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.